Wellgistics Health, INC

Wellgistics Health, Inc. has officially changed its corporate name to DataMeds AI, Inc., and will trade under the new symbol MEDS on the Nasdaq Capital Market starting July 22, 2026.

Wellgistics Health secured a Nasdaq compliance extension for stockholders' equity while confirming it has regained minimum bid price compliance.

Wellgistics Health announced the refinancing of its outstanding convertible debt and a $6.5 million capital raise, satisfying a key condition for a strategic transaction.

Wellgistics Health, Inc. has entered into a securities purchase agreement to raise $16.9 million in gross proceeds through the issuance of convertible promissory notes and warrants.

Wellgistics Health outlines a strategic shift towards vertical integration and blockchain technology to create essential healthcare infrastructure, enhancing efficiency and trust.

Wellgistics Health announces a significant strategic transaction involving multiple entities, aiming to create a new company valued at approximately $4 billion, alongside a 1-for-50 reverse stock split.

Wellgistics Health, Inc. reported a significant net loss of $34.3 million for Q3 2025 and $73.4 million year-to-date, raising substantial doubt about its ability to continue as a going concern.

Wellgistics Health, Inc. reported a dramatic increase in net loss to $39.1 million for the first half of 2025, raising substantial doubt about its ability to continue as a going concern, despite significant revenue growth from recent acquisitions.

Wellgistics Health's Q1 2025 results reflect the impact of recent acquisitions, with net sales reaching $10.9 million but a significant net loss reported.

Wellgistics Health, Inc. filed an amendment to its 2025 Annual Report to restate governance disclosures and include a formal clawback policy.

Wellgistics Health reported a significant net loss of $101.3 million for 2025, facing Nasdaq delisting concerns and substantial debt obligations.

Wellgistics Health, a holding company focused on pharmaceuticals and healthcare services, releases its Code of Business Conduct and Ethics and its annual report, detailing its business strategy and financial performance for the year ended December 31, 2024.

Director Surendra K. Ajjarapu acquired 100,000 shares of Wellgistics Health, Inc. common stock through the conversion of warrants.

Prashant Patel, CEO of Wellgistics Health, Inc., acquired 100,000 shares of common stock through the conversion of warrants.

Wellgistics Health, Inc. reports that CEO Prashant Patel was issued 5,000,000 shares of common stock and 5,000,000 warrants as compensation for services.

Wellgistics Health, Inc. reports that Director Surendra K. Ajjarapu was issued 5,000,000 shares of common stock and 5,000,000 warrants as compensation for services.

CEO Prashant Patel acquired 5,000,000 shares and 5,000,000 warrants of Wellgistics Health, Inc. as compensation for services.

Director Surendra K. Ajjarapu acquired 5,000,000 shares and 5,000,000 warrants of Wellgistics Health, Inc. as compensation for services.

Wellgistics Health, Inc. is holding a special meeting on May 21, 2026, to vote on a name change to Vantix Health Inc., authorizing preferred stock, and amending its equity incentive plan.

Wellgistics Health, Inc. announces the removal of two directors by majority shareholder consent and the appointment of four new directors, including a new President.

Wellgistics Health, Inc. is offering up to 5.36 million shares and warrants to raise $6.7 million, while detailing its strategic acquisitions and a novel blockchain-based payment and potential XRP treasury strategy.

Wellgistics Health, Inc. is launching a public offering of common stock and warrants to fund its integrated healthcare ecosystem and strategic blockchain-based payment initiatives.

Wellgistics Health, a micro health ecosystem company, filed an S-1/A for a public offering of common stock and warrants, detailing recent acquisitions, a new XRP treasury strategy, and significant financial losses.

Wellgistics Health, a healthcare and pharmaceutical holding company, has filed an S-1 registration statement for a public offering of common stock and warrants, while also disclosing a new strategic plan to integrate blockchain technology and hold XRP as a primary treasury reserve asset.

Wellgistics Health has filed a registration statement for the resale of up to 3,578,254 shares of its common stock by Hudson Global Ventures, LLC, stemming from an Equity Purchase Agreement.

Wellgistics Health, a holding company focused on pharmaceuticals and healthcare services, has filed an amendment to its Form S-1 registration statement for an initial public offering of 900,000 shares of common stock, with plans to list on the Nasdaq Capital Market under the symbol WGRX.